

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: TYLENOL
(ACETAMINOPHEN) MARKETING,
SALES PRACTICES AND
PRODUCTS LIABILITY
LITIGATION**

***THIS DOCUMENT RELATES TO ALL
CASES***

§
§
§
§
§
§
§
§

MDL NO. 2436

2:13-md-02436

HON. LAWRENCE F. STENGEL

**CASE MANAGEMENT ORDER NO. 17
(Discovery Related to Confidential Study Data)**

AND NOW, this 27th day of January, 2014, upon consideration of defendants' (McNeil and Johnson & Johnson) motion for protective order related to confidential study data and, in the alternative, request for entry of amended protective order for "highly confidential information" (Docket No. 81) and the PSC's opposition thereto (Docket No. 89) and after argument of both parties at the status conference with counsel on December 17, 2013, it is hereby **ORDERED** that in the defendants' motion is **DENIED** in part and **GRANTED** in part, as follows:

- 1) To the extent the defendants' motion sought protection from having to produce the discovery at issue because such information was beyond the scope of discovery and irrelevant to this litigation, that aspect of the motion is **DENIED**;
- 2) The court has determined that the information addressed in defendants' motion and sought by the PSC is discoverable and shall be produced, and therefore the alternative relief requested by the defendants, the entry of an Amended Protective Order (CMO 1, Doc. No. 104), is hereby **GRANTED**.

3) Defendants are to produce all responsive documents and information discussed in their motion (Doc. No. 81) which relate to or concern acetaminophen analogs and compounds and molecules added to acetaminophen to address liver toxicity in accord with Amended Case Management Order No. 1 (Doc. No. 104).

BY THE COURT:

/s/Lawrence F. Stengel
LAWRENCE F. STENGEL, J.